Download PDF
Thromb Haemost 2002; 87(03): 552-554
DOI: 10.1055/s-0037-1613047
Letters to the Editor
Schattauer GmbH

Thrombin Generation in a Reconstituted System: A Reply

Kenneth G. Mann
1   University of Vermont, College of Medicine, Burlington, Vermont, USA
,
Saulius Butenas
1   University of Vermont, College of Medicine, Burlington, Vermont, USA
› Author Affiliations
Further Information

Publication History

Received 05 November 2001

Accepted 21 November 2001

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Rand MD, Lock JB, van ’t Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-45.
    PubMedGoogle Scholar
  • 2 Cawthern KM, van ’t Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
    PubMedGoogle Scholar
  • 3 Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. J Biol Chem 1999; 274: 22862-70.
    CrossrefPubMedGoogle Scholar
  • 4 Holmes MB, Schneider DJ, Hayes MG, Sobel BE, Mann KG. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation 2000; 102: 2051-7.
    CrossrefPubMedGoogle Scholar
  • 5 Butenas S, Cawthern KM, van ’t Veer C, DiLorenzo ME, Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001; 97: 2314-22.
    CrossrefPubMedGoogle Scholar
  • 6 Butenas S, Branda RF, van ’t Veer C, Cawthern KM, Mann KG. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001; 86: 660-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-53.
    CrossrefPubMedGoogle Scholar
  • 8 Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood 2001; 98: 2423-31.
    CrossrefPubMedGoogle Scholar
  • 9 Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 23357-66.
    PubMedGoogle Scholar
  • 10 van ’t Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 1997; 272: 4367-77.
    CrossrefPubMedGoogle Scholar
  • 11 van ’t Veer C, Golden NJ, Kalafatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. J Biol Chem 1997; 272: 7983-94.
    CrossrefPubMedGoogle Scholar
  • 12 van ’t Veer C, Kalafatis M, Bertina RM, Simioni P, Mann KG. Increased tissue factor-initiated prothrombin activation as a result of the Arg506→Gln mutation in factor VLEIDEN. J Biol Chem 1997; 272: 20721-9.
    CrossrefPubMedGoogle Scholar
  • 13 Butenas S, van ’t Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272: 21527-33.
    CrossrefPubMedGoogle Scholar
  • 14 van ’t Veer C, Golden NJ, Kalafatis M, Simioni P, Bertina RM, Mann KG. An in vitro analysis of the combination of hemophilia A and factor VLEIDEN. Blood 1997; 90: 3067-72.
    CrossrefPubMedGoogle Scholar
  • 15 van ’t Veer C, Butenas S, Golden NJ, Mann KG. Regulation of prothrombinase activity by protein S. Thromb Haemost 1999; 82: 80-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Butenas S, van ’t Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94: 2169-78.
    PubMedGoogle Scholar
  • 17 van ’t Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
    PubMedGoogle Scholar
  • 18 Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. J Biol Chem 1994; 269: 23367-73.
    PubMedGoogle Scholar
  • 19 Mann KG. How much factor V is enough?. Thromb Haemost 2000; 83: 3-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Conard J, Brosstad F, Lie MLarsen, Samama M, Abilgaard U. Molar antithrombin concentration in normal human plasma. Haemostasis 1983; 13: 363-8.
    PubMedGoogle Scholar
  • 21 Beguin S, Kessels H, Dol F, Hemker HC. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity. Thromb Haemost 1992; 68: 136-42.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Perkins SL. Normal blood and bone marrow values in humans. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM. eds. Wintrobe’s Clinical Hematology. Philadelphia, PA: Lippincott Williams & Wilkins; 1999: 2738-48.
    Google Scholar
  • 23 Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Keularts IMLW, Zivelin A, Seligsohn U, Hemker HC, Beguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001; 85: 1060-5.
    Article in Thieme ConnectPubMedGoogle Scholar